Heart stent study aims to cut bleeding risk with shorter blood thinner course

NCT ID NCT07198529

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using a detailed imaging tool called optical coherence tomography (OCT) during heart stent placement can allow patients to stop taking blood thinners sooner. Patients with stable angina who receive a stent typically take two blood thinners for 6 to 12 months to prevent clots, but this raises bleeding risk. The trial will enroll 130 people and give them a shorter, 1-month course of dual therapy if OCT shows the stent is perfectly placed. Researchers hope this approach reduces bleeding without increasing heart attacks or stent clots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aspirin and clopidogrel (antiplatelet drugs)
What this could lead to
If successful, this could allow patients with stable angina to take blood thinners for a shorter time after stenting, lowering their risk of bleeding while still protecting against heart attacks.
What could go wrong
This is a small, early exploratory study at a single center, so results may not apply broadly. Shorter blood thinner use might increase the risk of stent clots or other heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cardiovascular Center, Department of Internal Medicine, Korea University Guro Hospital

    RECRUITING

    Seoul, Gurodong-ro, Guro-gu, 148, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.